Skip to content
Company Analysis

Cytek Biosciences, Inc. CTKB

A comprehensive view of key metrics, scores, and financial health for Cytek Biosciences, Inc.

Overview of Cytek Biosciences, Inc.

CTKB NMS
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Small Cap
Cytek Biosciences, Inc. (CTKB), is a Small Cap company, in the Medical Devices industry, last closed at $5.77, about 67.4% overvalued vs fair value, +27.1% 1Y return, ranked 771/1145 in sector.
Metrics Rev Growth 0.5% ROE -18.1% Gross Margin 51.8%
USD 5.77
-5.87%
(Delayed)
• Vol 90d: 47.9%
52-Week Range
Market Cap
$750.00M
Enterprise Value
$685.83M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Good
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Good
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 88%
Confidence: 93%
Updated: Oct 31
Top Beats

Quick Facts

Website https://cytekbio.com
HQ Fremont, CA
Employees 692
Fiscal year Dec 31

Next Events

Earnings Nov 4 Call: Nov 4

Fair Value Snapshot

Bear Base Bull
$2
$2
$2
Current: $5.77 -67% vs base

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$201.5M
0.5%%
Gross Profit
$104.5M
-6%%
Operating Income (GAAP)
-$40.4M
-96.8%%
EBITDA
-$17.4M
-73.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
51.8%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Cytek Biosciences, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
50
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Durable Capital Returns ROIC durability is strong (score 0.86). Consistent returns confirm the moat is not eroding.
  • Conservative Leverage Leverage position is conservative vs peers (score 0.81). Balance sheet flexibility is a strategic asset for serial acquirers.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.40). May indicate commodity-like product mix or distributor margin drag.
  • Thin Interest Coverage Interest coverage lags peers (score 0.17). Thin coverage limits M&A optionality and raises refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
43
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing CTKB's balance between Growth (22.1%), Profitability (34.4%), and Safety (43.4%). Growth 22% Safety 43% Profitability 34%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

31th percentile vs peers
32
Key Signals
Revenue CAGR 3Y 7.1% 51p Rev Growth YoY 0.5% 33p TSR -10.6% 46p Asset Growth YoY -7.6% 29p EPS Growth YoY -10.30 2p
Strengths
  • Net Debt/EBITDA in top 20% of peers (-30.95, 98th percentile)
  • Debt/Assets in top 20% of peers (5.1%, 80th percentile)
  • Conservative leverage compared to industry peers
Risks
  • EPS Growth YoY in bottom 20% of peers (-10.30)
  • Growth below peer median (percentile: 31)

Profitability

49th percentile vs peers
50
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

62th percentile vs peers
63
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Cytek Biosciences, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$1.88
- - -
-67.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000